Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022195096 - PEPTIDE AND METHOD FOR DIRECT ANALYSIS OF SARS-COV-2 IMMUNE RESPONSES

Publication Number WO/2022/195096
Publication Date 22.09.2022
International Application No. PCT/EP2022/057212
International Filing Date 18.03.2022
IPC
G01N 33/569 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
C07K 14/005 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
CPC
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2770/20022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/20034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
G01N 2333/165
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
G01N 33/56983
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
56983Viruses
Applicants
  • CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN [DE]/[DE]
Inventors
  • THIEL, Andreas
  • LOYAL, Lucie
  • HENZE, Larissa
  • BRAUN, Julian
Agents
  • HERTIN UND PARTNER RECHTS- UND PATENTANWÄLTE
Priority Data
21163756.619.03.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PEPTIDE AND METHOD FOR DIRECT ANALYSIS OF SARS-COV-2 IMMUNE RESPONSES
(FR) PEPTIDE ET PROCÉDÉ D'ANALYSE DIRECTE DE RÉPONSES IMMUNITAIRES AU SRAS-COV-2
Abstract
(EN) The invention relates to a peptide comprising or consisting of an amino acid sequence FIEDLLFNKVT (SEQ ID NO 1) or a sequence of at least 80%, preferably at least 90%, sequence identity thereto. In embodiments, the peptide is of up to 25 amino acids, or 15-25 amino acids. The invention further relates to a nucleic acid molecule encoding the peptide of the invention, a solid phase comprising the peptide of the invention, an in vitro method for assessing the risk of a subject in developing a severe acute respiratory syndrome (SARS) or other adverse event or severe medical condition associated with SARS-CoV infection, comprising use of the peptide of the invention, the peptide of the invention for use in an immunogenic composition, such as a vaccine, a kit for performing the method, and a method for assessing the functional avidity of T cells for one or more antigens, employing the peptide of the invention.
(FR) L'invention concerne un peptide comprenant ou constitué d'une séquence d'acides aminés FIEDLLFNKVT (SEQ ID NO 1) ou d'une séquence présentant au moins 80 %, de préférence au moins 90 %, d'identité de séquence avec cette dernière. Dans des modes de réalisation, le peptide est constitué de jusqu'à 25 acides aminés, ou de 15 à 25 acides aminés. L'invention concerne en outre une molécule d'acide nucléique codant pour le peptide de l'invention, une phase solide comprenant le peptide de l'invention, un procédé in vitro pour évaluer le risque pour un sujet de développer un syndrome respiratoire aigu sévère (SRAS) ou un autre événement indésirable ou une affection médicale sévère associée à une infection par le SARS-CoV, comprenant l'utilisation du peptide de l'invention, le peptide de l'invention destiné à être utilisé dans une composition immunogène, tel qu'un vaccin, un kit pour la mise en œuvre du procédé, et un procédé d'évaluation de l'avidité fonctionnelle de lymphocytes T pour un ou plusieurs antigènes, utilisant le peptide de l'invention.
Latest bibliographic data on file with the International Bureau